세계 첫 암백신 임상 3상 성공...개인맞춤형 항암치료 시대, 한 발짝 앞으로
Moderna and MSD (American Merck) are jointly developing an mRNA-based personalized treatment drug called 'Intismeilan Autozin' for cancer patients. This trial, the first of its kind globally, has shown promising results in the third-phase clinical study. The drug, often referred to as an 'immunocancer vaccine,' combines targeted therapy with immunotherapy to treat melanoma, a type of skin cancer.
In a study of 1,137 patients, combining the drug with 'Kitruda' chemotherapy significantly reduced the risk of recurrence and metastasis in high-risk patients with melanoma after complete surgical removal. The results indicate that this personalized treatment approach could redefine the way we approach cancer therapy.
Written by urgent.news from Hankyoreh's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- An Se-young has reclaimed her world championship title after three years, dominating the competition from the qualifying rounds to the final with a 'perfect victory'. hani.co.kr
- It has been three years since the treated water was released, and the seafood price has plummeted due to the import ban, with some people giving up on compensation. asahi.com
